bluebird bio(us:BLUE)
5.25
+7.58%
Updated on 2025-04-02
Open:4.86
Close:5.25
High:5.37
Low:4.82
Prev Close:4.88
Volume:860044.00
Turnover:4.39M
Turnover Ratio:8.78%
Shares:9.79M
MarketCap:51.40M
Total 4 records
| code | change | total | increase | decrease | rps5 | rps10 | rps15 | rps20 |
|---|---|---|---|---|---|---|---|---|
Biotechnology BK2069 | -3.40% | 667 | 116 | 528 | 8 | 6 | 4 | 11 |
CAR-T Therapy BK2113 | -3.76% | 10 | 3 | 7 | 52 | 21 | 15 | 39 |
Top Gainers Yesterday BK2542 | +6.19% | 74 | 84 | 178 | 44 | 4 | 0 | 0 |
Gene Editing BK2569 | -0.61% | 10 | 2 | 8 | 22 | 10 | 19 | 45 |
About
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.
Address:455 Grand Union Boulevard
Website:http://www.bluebirdbio.com
Market Movers